(Q54352756)

28 May 2018

http://europepmc.org/abstract/MED/24827132

title

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. (English)

1 reference

28 May 2018

http://europepmc.org/abstract/MED/24827132

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

A Kramar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

T Bachelot

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

N Madrange

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

J-Y Pierga

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

P Kerbrat

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Espié

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

P Fumoleau

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

I Pauporté

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

D Khayat

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

G Romieu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

14 May 2014

1 reference

28 May 2018

http://europepmc.org/abstract/MED/24827132

published in

Annals of Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

1563-1570

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827132%20AND%20SRC:MED&resulttype=core&format=json

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

The challenge of subgroup analyses--reporting without distorting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU177